Next Investors logo grey

BDA's Cannabidiol (Cannabis) Product to Treat Insomnia


Published 22-SEP-2021 13:32 P.M.


4 minute read

It might not be long before Aussies can pop into their local pharmacy to buy cannabidiol (CBD) products to help them sleep better.

Our cannabis and healthcare investment, Bod Australia (ASX:BDA) has plans to help customers achieve better sleep with news today that it has entered into an agreement to undertake a Phase IIB clinical trial with Australia’s leading respiratory and sleep institute.

BDA announced that the Woolcock Institute will undertake a Phase IIB clinical trial for the development of a new CBD product to treat insomnia that it hopes to make available in Australian pharmacies, as well as other key international markets.

This follows the Therapeutic Goods Administration’s (TGA) landmark decision in December 2020 that down-scheduled CBD to a Schedule 3 from a Schedule 4 (Prescription Only Medicine). This paved the way for CBD products to be purchased as over-the-counter treatments at pharmacies from July 2021.

Since that decision, there are still no TGA-approved CBD products that pharmacists can prescribe. But BDA hopes to pioneer change in this area.

So far, BDA is one of only two companies with clinical trials in the works, with Ecofibre Ltd also undertaking clinical studies to evaluate the efficacy of CBD on sleep disturbance.

We think that BDA might have the edge because its capsule uses a higher dosage than Ecofibre’s 15mg soft gel solution.

Phase IIB clinical trials will identify the ideal dosage level of CBD to improve a person’s quality of sleep, and we think that BDA’s higher dosage solution, coupled with its encapsulation technology, will maximize the efficiency of delivering the drug.

We like that BDA is developing pharmaceutical grade products as they are generally more valuable, and deliver higher margins to companies that sell them.

For BDA, the prize of a successful clinical trial is substantial. The domestic Schedule 3 cannabis market is worth $250M, while the unregulated market is estimated to be worth some ~$3.5BN.

Furthermore, the potential opportunity worldwide is huge. The global market for insomnia solutions is estimated to reach $5.48BN by 2023 — growing at an annual rate (CAGR) of 4.2% from 2017.

The Phase IIB clinical trial design has now been finalised to test the efficacy of BDA’s unique CBD formulation among adults aged 18 to 65 years old who experience insomnia.

As we mentioned above, the study will be performed at the Woolcock Institute of Medical Research — the top specialist sleep and respiratory health research centre in the world. The trial will run for a total of 12 weeks with approximately 200 participants.

BDA CEO Jo Patterson is confident that the successful completion of the study will lead to major commercial opportunities for the company. This comes down to BDA’s "existing distribution networks, established partnership with H&H, relationships with other groups, and a rapidly developing market for Schedule 3 products with fewer side effects than existing offerings".

Following product registration through the TGA, BDA will leverage its established relationship with Swisse Vitamins parent company, H&H Group, Swisse Wellness and other parties to drive sales growth.

And while focusing on the Australian market initially, BDA is chasing additional commercial opportunities via product registration with the European EMEA Union and the US FDA.

For those new to the story, BDA is an Australian medicinal cannabis, cannabidiol (CBD), and hemp healthcare company that delivers products for the consumer and medicinal markets. It operates under two core businesses:

  1. Medicinal Cannabis — focused on sales of its established MediCabilis product in Australia and the UK; and
  2. CBD Wellness — under which all of BDA’s 30+ products are licenced to Swisse Vitamins’ H&H Group. These products are sold and distributed in the UK, Italy, Netherlands, Australia and the USA.

Unlike a lot of small cap cannabis stocks, we like that BDA is already generating decent and growing revenues.

Another of BDA’s points of difference is their established relationship with H&H and Swisse Wellness. Think of BDA as creating new products through research and development , with H&H and Swisse Wellness providing distribution, sales and marketing.

Science led product innovation and development is core to the BDA strategy, and we look forward to seeing if BDA can capitalise on the new TGA rules and commercialise this new product application.

What we are watching out for next:

Research & Development

[NEW] Insomnia Study (Schedule 3 CBD Australia)

Partnership with Woolcock Institute of Medical Research

✅ Phase IIB Trial Design Finalised

🔲 Ethics Approval for Study

🔲 Patient Recruitment Commenced

🔲 Phase IIB Trials

🔲 Phase IIB Trial Results

🔲 Submission of data to TGA

🔲 Product Registered

🔲 Product Licence / Commercialised

Our investment strategy for BDA

While it’s still very early in our investment journey, we have been impressed with BDA’s product development progress since our investment in March 2021, even though its shares have been regularly sold down since then.

However, today’s news appears to have been well received by the market, and we expect a recovery once BDA starts making a profit and medical cannabis stocks come back into investor favour.

Our investment followed extensive due diligence on the company and the sector and we remain confident of earning a solid return on our investment. There’s still a long way to go in our 4 to 7 year investment time frame:

Initial Investment: @ 50.5c

🔲 Increase Investment 1

🔲 Increase Investment 2

🔲 Price increases 250% from initial entry

🔲 Price increases 500% from initial entry

🔲 Price increases 1000% from initial entry

🔲 12 Month Capital Gain Discount

🔲 Free Carry

🔲 Take Some Profit

🔲 Hold remaining Position for next 2+ years

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.